Axsome Therapeutics AXSM incurred an adjusted loss of 97 cents per share in the second quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of $1.00. The company had incurred a loss ...

Q2 2025 Earnings Call Transcript August 4, 2025 Axsome Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.92 ...

Axsome Therapeutics Inc (AXSM) reports a 72% year-over-year revenue increase, driven by strong product sales and strategic ...

Total 2Q 2025 net product revenue of $150.0 million, representing growth of 72% year-over-year and 24% sequentially AUVELITY® ...

Double-digit prescription gains for its commercial drugs, major coverage wins, and the early launch of a new migraine therapy were the most significant highlights. Despite substantial progress, the ...

Discover Axsome Therapeutics' Q2 2025 earnings highlights, including 72% revenue growth, new product launch SYMBRAVO, and promising neuroscience ...

Key Points Shopify's moat and vast runway for growth make its prospects highly attractive. Axsome Therapeutics has a robust late-stage pipeline that should lead to important approvals.10 stocks we ...

Axsome Therapeutics reported quarterly losses of 47 cents per share compared to analyst consensus estimate of losses of $1.07 per share. The company reported quarterly sales of $150.04 million which ...

Axsome's valuation is driven by its promising pipeline, with Auvelity as a proven commercial success and Symbravo and AXS-12 showing solid potential. Recent setbacks include the FDA's refusal to ...

Axsome Therapeutics reported record total product revenues of $150 million for the quarter, marking a 72% increase year-over-year and a 24% increase quarter-over-quarter. This impressive growth ...

Investing.com - Cantor Fitzgerald has reiterated an Overweight rating and $153.00 price target on Axsome Therapeutics (NASDAQ: AXSM) following the company’s R&D Day. The research firm ...

Mizuho does not expect the R&D Day to serve as a significant catalyst for the stock but views any additional information regarding progress with the submission of the supplemental New Drug Application ...